Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.47 |
| ▸ | MDM4 | O15151 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22433653 | 0.95 | BACE1 (0.52) | BACE1MDM2PRMT5WDR77MDM4 | |
| SCHEMBL30133561 | 0.93 | MDM2 (0.50) | BACE1MDM2PRMT5WDR77MDM4 | |
| SCHEMBL24979705 | 0.86 | BACE1 (0.47) | BACE1MDM2MDM4TP53TLR2 | |
| SCHEMBL22433654 | 0.86 | BACE1 (0.47) | BACE1MDM2MDM4TP53TLR2 | |
| SCHEMBL31688984 | 0.85 | BACE1 (0.51) | BACE1MDM2MDM4TP53TLR2 | |
| SCHEMBL25355242 | 0.84 | BACE1 (0.53) | BACE1MDM2MDM4TP53TLR2 | |
| SCHEMBL5434114 | 0.84 | BACE1 (0.53) | BACE1MDM2MDM4TP53TLR2 | |
| SCHEMBL25356332 | 0.84 | BACE1 (0.53) | BACE1MDM2MDM4TP53TLR2 | |
| SCHEMBL31627392 | 0.84 | BACE1 (0.53) | BACE1MDM2MDM4TP53TLR2 | |
| SCHEMBL25357033 | 0.83 | TLR2 (0.51) | BACE1MDM2MDM4TP53TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358951-B2 | Cyclic peptide antibiotics | GENENTECH, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20230025834-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025834-A1 | CYCLIC PEPTIDE ANTIBIOTICS | NPPA, LNPEP, CLPP | BACE1 404/4885MDM2 2362/4885PRMT5 2783/4885 |
| US-12358951-B2 | Cyclic peptide antibiotics | NPPA, LNPEP, CLPP | BACE1 404/4885MDM2 2362/4885PRMT5 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.